ESPR Esperion Therapeutics Inc

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C.

$6.45  +0.09 (1.42%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2013
Outstanding shares:  63,006,619
Average volume:  872,873
Market cap:   $400,722,097
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BBNBTD2
Valuation   (See tab for details)
PE ratio:   -1.73
PB ratio:   20.03
PS ratio:   4.49
Return on equity:   94.32%
Net income %:   -263.04%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy